Abstract：
BACKGROUND: The goal of this research is to investigate the clinical characteristics and prognosis of men with metastatic breast cancer (mMBC).
METHODS: A retrospective analysis of the data of 28 patients was conducted. Kaplan-Meier and Cox regression analyses were used to assess overall survival (OS) and prognostic variables.
RESULTS: At the time of diagnosis, the median age was 57 years (range 26-86). The most prevalent pathological subtype was invasive ductal carcinoma (92.6%). HER2 positivity was 21.6% in patients, with estrogen and progesterone receptor positivity at 96.4% and 71.4%, respectively. Bone-75%, lung-39.3%, brain-21.4%, and adrenal gland-10.7% were the most prevalent metastatic sites. Trastuzumab-based chemotherapy was given to six patients. During the study period, 14 patients (or half) died. All patients had a median OS of 42.6 months (range: 21.6-63.7). The OS rates after 1, 3, and 5 years were 95.7%, 54.2%, and 36.6%, respectively. The number of metastatic locations (P = 0.045), brain metastasis (P = 0.033), and a history of regular alcohol intake (P = 0.008) were all shown to be statistically significant factors affecting OS in univariate analysis. However, multivariate analysis did not support the findings. In addition, we discovered that trastuzumab-based therapy and de-novo metastatic disease had no effect on OS for mMBC.
CONCLUSIONS: The data on mMBC is restricted because of its rarity. The prognosis of mMBC was shown to be poor in this investigation. Despite the small number of patients, we discovered that in univariate analysis, having brain metastases, the number of metastatic locations, and a history of alcohol intake may be prognostic factors.
METHODS: A retrospective analysis of the data of 28 patients was conducted. Kaplan-Meier and Cox regression analyses were used to assess overall survival (OS) and prognostic variables.
RESULTS: At the time of diagnosis, the median age was 57 years (range 26-86). The most prevalent pathological subtype was invasive ductal carcinoma (92.6%). HER2 positivity was 21.6% in patients, with estrogen and progesterone receptor positivity at 96.4% and 71.4%, respectively. Bone-75%, lung-39.3%, brain-21.4%, and adrenal gland-10.7% were the most prevalent metastatic sites. Trastuzumab-based chemotherapy was given to six patients. During the study period, 14 patients (or half) died. All patients had a median OS of 42.6 months (range: 21.6-63.7). The OS rates after 1, 3, and 5 years were 95.7%, 54.2%, and 36.6%, respectively. The number of metastatic locations (P = 0.045), brain metastasis (P = 0.033), and a history of regular alcohol intake (P = 0.008) were all shown to be statistically significant factors affecting OS in univariate analysis. However, multivariate analysis did not support the findings. In addition, we discovered that trastuzumab-based therapy and de-novo metastatic disease had no effect on OS for mMBC.
CONCLUSIONS: The data on mMBC is restricted because of its rarity. The prognosis of mMBC was shown to be poor in this investigation. Despite the small number of patients, we discovered that in univariate analysis, having brain metastases, the number of metastatic locations, and a history of alcohol intake may be prognostic factors.
摘要：
背景：本研究的目的是探讨男性转移性乳腺癌（mMBC）的临床特征和预后。
方法：对28例患者的资料进行回顾性分析。Kaplan-Meier和Cox回归分析用于评估总生存期（OS）和预后变量。
结果：在诊断时，中位年龄为57岁(26-86岁).最常见的病理亚型是浸润性导管癌（92.6％）。患者的HER2阳性率为21.6%，雌激素和孕激素受体阳性率分别为96.4%和71.4%，分别。骨-75%,肺-39.3%，大脑-21.4%，肾上腺-10.7%是最常见的转移部位。对6例患者给予以曲妥珠单抗为基础的化疗。在学习期间,14例（或一半）患者死亡。所有患者的中位OS为42.6个月（范围：21.6-63.7）。术后1年、3年和5年的OS率为95.7%，54.2%,和36.6%，分别。转移部位数(P=0.045),脑转移（P=0.033），在单因素分析中,定期饮酒史(P=0.008)均显示为影响OS的统计学显著因素.然而,多变量分析不支持这一发现.此外,我们发现以曲妥珠单抗为基础的治疗和新生转移性疾病对mMBC的OS无影响.
结论：关于mMBC的数据由于其稀有性而受到限制。在这项研究中，mMBC的预后较差。尽管患者人数很少，我们发现在单变量分析中，有脑转移,转移部位的数量，饮酒史可能是预后因素。
方法：对28例患者的资料进行回顾性分析。Kaplan-Meier和Cox回归分析用于评估总生存期（OS）和预后变量。
结果：在诊断时，中位年龄为57岁(26-86岁).最常见的病理亚型是浸润性导管癌（92.6％）。患者的HER2阳性率为21.6%，雌激素和孕激素受体阳性率分别为96.4%和71.4%，分别。骨-75%,肺-39.3%，大脑-21.4%，肾上腺-10.7%是最常见的转移部位。对6例患者给予以曲妥珠单抗为基础的化疗。在学习期间,14例（或一半）患者死亡。所有患者的中位OS为42.6个月（范围：21.6-63.7）。术后1年、3年和5年的OS率为95.7%，54.2%,和36.6%，分别。转移部位数(P=0.045),脑转移（P=0.033），在单因素分析中,定期饮酒史(P=0.008)均显示为影响OS的统计学显著因素.然而,多变量分析不支持这一发现.此外,我们发现以曲妥珠单抗为基础的治疗和新生转移性疾病对mMBC的OS无影响.
结论：关于mMBC的数据由于其稀有性而受到限制。在这项研究中，mMBC的预后较差。尽管患者人数很少，我们发现在单变量分析中，有脑转移,转移部位的数量，饮酒史可能是预后因素。
